Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Severe-immune mediated enteropathy describes a variety of intestinal disorders that can range from a serious, early-onset systemic disease (IPEX) to a mild isolated gastrointestinal disease. In children it manifests with severe diarrhea and dehydration in the presence of characteristic antibodies (anti-enterocyte and anti-goblet cell) and in adults with chronic diarrhea, malabsorption and weight loss.
No HPO annotations are available for this condition.
Age of onset: infancy.
IPEX syndrome is generally considered to be a syndrome of neonatal enteropathy and neonatal polyendocrinopathy found in males. In a large natural history study, 95% of individuals with IPEX syndrome had disease onset in the first year of life, with 50% by age one month . However, atypical clinical presentation has been reported with onset later in childhood . Presentation. The most common presentation of IPEX syndrome is malabsorption with severe watery diarrhea, type 1 insulin-dependent diabetes mellitus, thyroiditis, and dermatitis in males younger than age one year. This disorder is frequently accompanied by other autoimmune phenomena. Males with a somewhat milder/atypical disease phenotype can present at older ages .
The term "IPEX" is an acronym for immune dysregulation, polyendocrinopathy, enteropathy, X-linked.
IPEX syndrome should be suspected in males with the following clinical triad, family history, and suggestive laboratory findings.
Clinical triad
Source: GeneReviews — "IPEX Syndrome"
No approved treatments are currently available for autoimmune enteropathy. The disease remains an area of unmet medical need.
To establish the extent of disease in an individual diagnosed with IPEX syndrome, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 3.
IPEX Syndrome: Recommended Evaluations Following Initial Diagnosis
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended.
Table 5.
IPEX Syndrome: Recommended Surveillance
System/Concern | Evaluation | Frequency
| Monitor growth, nutritional intake, stooling patterns. | At each visit
1 clinical trial registered. Interventions under study include gene therapy. Research is primarily sponsored by academic and government institutions.
150 publications have been identified in PubMed for autoimmune enteropathy. Research spans Review / Meta-Analysis (33%), Case Report / Case Series (21%), and Basic Science / Preclinical (19%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 47 | 33% |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 12:17 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Source: GeneReviews — "IPEX Syndrome"
IPEX syndrome is classified by the International Union of Immunological Societies (IUIS) as an inborn error of immunity that results in immune dysregulation due to absent or defective regulatory T cells (Treg) . Autoimmunity is the primary clinical manifestation. Among the ten unique disorders with Treg dysfunction, LRBA deficiency, CTLA4 haploinsufficiency, CD25 deficiency, FERMT1 deficiency, BACH2 deficiency, IKAROS GOF (gain of function), and CD122 deficiency have the most clinical overlap with IPEX syndrome . Other inborn errors of immunity without Treg dysfunction, including immune dysregulation with colitis, can also mimic IPEX syndrome . In addition to immune dysregulation disorders, monogenic forms of neonatal diabetes that are clinically evident soon after birth can present similarly to IPEX syndrome. These conditions are most commonly associated with pancreatic defects and lack autoimmune manifestations . Similarly, intrinsic defects of the intestinal microvilli have clinical presentations consistent with enteropathy with malabsorption and diarrhea but are not immune mediated . See for these and other considerations in the differential diagnosis. Table 2. Syndromes of Known Genetic Cause to Consider in the Differential Diagnosis of IPEX Syndrome
Gene(s)/ Genetic Mechanism | Disorder | MOI | Additional Key Features |
|---|---|---|---|
BACH2 | BACH2-related immunodeficiency autoimmunity2 | AD | Enteropathy, chronic variable immunodeficiency |
CTLA4 | CTLA4 haploinsufficiency (autoimmune lymphoproliferative syndrome, type V) (OMIM 616100) | AD | Enteropathy, autoimmune cytopenias, autoimmune thyroiditis |
FERMT1 | FERMT1 deficiency | AR | Gingivitis, periodontitis, mucosal inflammation |
IKZF1 | IKAROS GOF (OMIM 616873) | AD | Low Treg numbers, immune deficiency, autoimmune disease; Distinguished from IPEX syndrome by low B cell numbers3 |
IL2RA | CD25 deficiency (OMIM 606367) | AR | Identified in 3 persons w/IPEX syndrome-like clinical phenotype. |
Source: GeneReviews — "IPEX Syndrome"
Biomarker and diagnostic research for autoimmune enteropathy has been reported in the published literature.
| Nutrition assessment incl serum electrolyte levels, calcium, magnesium, zinc, serum albumin, pre-albumin | The majority of persons will require discontinuation of enteral feeding initiation of TPN.
Hepatic assessment | Incl serum AST, ALT, GGT, total bilirubin, assessment of hepatic autoantibodies
Small bowel biopsy incl specific staining for Treg | To assess response to treatment
| • Glucose tolerance test
Hemoglobin A1c
Thyroid function tests
Autoantibodies to pancreatic islet antigens thyroid antigens
|
| Eval of any skin lesions | Should incl biopsy for histology
| • Serum IgG, IgM, IgA, IgE concentrations
Lymphocyte enumeration by flow cytometry
Lymphocyte response to mitogens
| Serum immunoglobulins, lymphocyte enumeration, mitogen proliferation to assess cellular immune reconstitution following HSCT
| • Complete blood count differential
Coombs test
Eval of autoimmune hypercoagulability (anti-phospholipid antibodies, lupus anticoagulant)
|
| • BUN, creatinine
Urinalysis
|
| By genetics professionals1 | To inform affected persons their families re nature, MOI, impl...
Source: GeneReviews — "IPEX Syndrome"
Immune activation (e.g., by immunizations or severe infections) has been reported to cause worsening or exacerbation of disease symptoms . It is generally best practice to withhold immunizations until after HSCT, if possible.
Source: GeneReviews — "IPEX Syndrome"
HSCT carries the risk of significant morbidity and mortality, and suitable donors are not always available. For these and other reasons, IPEX syndrome is an excellent candidate for treatment with gene therapy. However, one major hurdle is the need to regulate the expression of FOXP3 on mature T cells; thus, hematopoietic stem cells are not the ideal target for gene delivery. An alternative approach has been to convert CD4+ T cells from individuals with IPEX syndrome using lentivirus vectors that carry normal FOXP3. Lentiviral delivery of exogenous FOXP3 cDNA is accomplished under the constitutive promoter to achieve conversion of FOXP3 mutated cells to normal functioning regulatory T cells (Treg) in vivo.
Source: GeneReviews — "IPEX Syndrome"
1 trial found
| • Glucose tolerance test
Hemoglobin A1c
Thyroid function tests
| Every 3-6 mos
| Skin exam | At each visit
| • Complete blood count
BUN, creatinine
Urinalysis
Serum AST, ALT
| Every 3-6 mos
ALT = alanine transferase; AST = aspartate transferase; BUN = blood urea nitrogen
Source: GeneReviews — "IPEX Syndrome"
Patient case studies |
29 |
21% |
Laboratory research | 27 | 19% |
Disease patterns and progression | 16 | 11% |
Testing and diagnosis research | 12 | 9% |
Clinical study results | 8 | 6% |
Other research | 1 | 1% |
New treatment approaches | 1 | 1% |
Lu JT (2026). [PMID: 41743217](https://pubmed.ncbi.nlm.nih.gov/41743217/). *Mediators Inflamm*. [Diagnostic / Biomarker]
Li MH (2026). [PMID: 41551832](https://pubmed.ncbi.nlm.nih.gov/41551832/). *World J Gastroenterol*. [Review / Meta-Analysis]
Butler K (2026). [PMID: 41782401](https://pubmed.ncbi.nlm.nih.gov/41782401/). *Curr Opin Gastroenterol*. [Review / Meta-Analysis]
Vivier Chicoteau J (2026). [PMID: 41309320](https://pubmed.ncbi.nlm.nih.gov/41309320/). *Bull Cancer*. [Review / Meta-Analysis]
Mortensen JK (2026). [PMID: 41593674](https://pubmed.ncbi.nlm.nih.gov/41593674/). *Acta Vet Scand*. [Case Report / Case Series]
Litsou E (2026). [PMID: 42195197](https://pubmed.ncbi.nlm.nih.gov/42195197/). *Medicina (Kaunas)*. [Review / Meta-Analysis]
Thakkar B (2026). [PMID: 42158908](https://pubmed.ncbi.nlm.nih.gov/42158908/). *ACG Case Rep J*. [Case Report / Case Series]
Lv J (2026). [PMID: 41593440](https://pubmed.ncbi.nlm.nih.gov/41593440/). *Am J Chin Med*. [Review / Meta-Analysis]
Hill K (2026). [PMID: 41509630](https://pubmed.ncbi.nlm.nih.gov/41509630/). *FASEB Bioadv*. [Basic Science / Preclinical]
De Biasi J (2026). [PMID: 42148824](https://pubmed.ncbi.nlm.nih.gov/42148824/). *Nutr Rev*. [Review / Meta-Analysis]